Viyash Scientific share price
NSE: VIYASHBSE: 512529Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹207.99.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹9,017 Cr598th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 May 2026
- 3.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 11.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 19 May 2026
- 0.14
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 44,68,18350.3% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 11 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹946 Crup 2.87%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹79 Crup 19.45%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 8.4%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
The years either side of a change of basis do not compare. From the year to Mar 2018, the company's revenue for that year, ₹849 Cr, differs from its quarters added, ₹983 Cr; GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty. From the year to Mar 2021, the company's revenue for that year, ₹1,362 Cr, differs from its quarters added, ₹1,377 Cr. From the year to Mar 2026, the company's revenue for that year, ₹3,420 Cr, differs from its quarters added, ₹2,644 Cr.
| ₹ crore | Sep 2024Filed 14 Nov | Dec 2024Filed 11 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 8 Aug | Sep 2025Filed 14 Nov | Dec 2025Filed 5 Feb | Mar 2026Filed 19 May | Jun 2026Filed 11 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 369 | 391 | 402 | 441 | 424 | 858 | 920 | 946 |
| Net profit | 6 | 6 | 10 | 18 | 20 | 49 | 66 | 79 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 1.7% | 1.7% | 2.6% | 4.0% | 4.6% | 5.7% | 7.2% | 8.4% |
The quarters either side of a change of basis do not compare. From the quarter to Mar 2026, the company's revenue for the year to Mar 2026, ₹3,420 Cr, differs from its quarters added, ₹2,644 Cr.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement. Its history crosses a change of basis in the accounts in the years to Mar 2018, Mar 2021 and Mar 2026: days before it are of the company before the change.PE ratio and valuation history
At or below today's level on 27% of 1,854 trading days since Nov 2018.
At or below today's level on 15% of 1,854 trading days since Nov 2018.
At or below today's level on 70% of 2,458 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +39.7% | +364.8% | −69.9% | 0.0% |
| 3 years | +36.0% | – | – | 0.0% |
| 5 years | −5.4% | +1.1% | −6.4% | 0.0% |
Mutual funds holding it
27 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 9 of the 12 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 11
- CutCut. Funds that held fewer shares than at the end of the month before.
- 1
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 14
| Fund | |||
|---|---|---|---|
 Bandhan Large & Mid Cap FundBandhan Mutual Fund | 54,41,785 | 0.62% | ₹128.3 Cr |
 Kotak Multi Asset Allocation FundKotak Mahindra Mutual Fund | 45,41,722 | 0.70% | ₹107.1 Cr |
 Edelweiss Small Cap FundEdelweiss Mutual Fund | 36,05,508 | 1.21% | ₹85.0 Cr |
| Kotak ELSS Tax Saver FundKotak Mahindra Mutual Fund | 35,17,910 | 1.37% | ₹83.0 Cr |
| Bandhan Small Cap FundBandhan Mutual Fund | 21,77,500 | 0.14% | ₹51.3 Cr |
| Kotak Manufacture in India FundKotak Mahindra Mutual Fund | 20,82,301 | 1.57% | ₹49.1 Cr |
| Kotak Contra FundKotak Mahindra Mutual Fund | 19,76,797 | 0.90% | ₹46.6 Cr |
| Kotak Special Opportunities FundKotak Mahindra Mutual Fund | 17,68,838 | 2.17% | ₹41.7 Cr |
| Kotak MNC FundKotak Mahindra Mutual Fund | 12,36,000 | 1.30% | ₹29.1 Cr |
| Kotak Balanced Advantage FundKotak Mahindra Mutual Fund | 11,43,827 | 0.16% | ₹27.0 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Viyash Scientific in market cap.
Viyash Scientific is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Concord BiotechCONCORDBIO | 12,860 | 46.7 | 6.4 | 33.1 | −6.7% | −22.7% | 14.4% | 15.6% | 0.61% |
 CORONA RemediesCORONA | 12,545 | 63.0 | 16.8 | 39.9 | – | – | 26.6% | 30.9% | 0.49% |
 Akums Drugs and PharmaceuticalsAKUMS | 10,530 | 36.1 | 3.2 | 15.7 | +9.2% | −14.6% | 9.2% | 12.0% | 0.45% |
 Strides Pharma ScienceSTAR | 9,354 | 15.2 | 3.0 | 11.5 | +7.3% | – | 21.7% | 15.1% | 0.49% |
 Blue Jet HealthcareBLUEJET | 9,001 | 38.3 | – | – | −27.5% | −34.5% | 18.8% | 18.1% | 0.25% |
 Procter & Gamble HealthPGHL | 8,325 | 23.3 | 15.9 | 17.5 | – | – | 67.2% | 84.2% | 4.09% |
 Symbiotec PharmalabSYMBIOTEC | 7,481 | – | – | – | – | – | – | – | 0.00% |
 Aarti PharmalabsAARTIPHARM | 7,443 | – | 3.5 | 19.0 | +1.2% | – | – | 11.2% | 0.43% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 8 Sep 2021 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
| 21 Aug 2019 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.20 |
| 20 Nov 2017 | Interim | ₹0.20 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
20 Oct · Management
8 Oct · General Updates
Sep 2026
18 Sep · General Updates
8 Sep · General Updates
Viyash Scientific share price by year
Each calendar year to 2025.Viyash Scientific share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 208.54 | +18.6% | 252.00 | 126.68 |
| 2024 | 175.86 | +54.6% | 232.22 | 98.90 |
| 2023 | 113.75 | +29.9% | 126.50 | 62.25 |
| 2022 | 87.60 | −45.6% | 191.70 | 83.15 |
| 2021 | 160.95 | −5.1% | 323.60 | 150.90 |
| 2020 | 169.55 | +139.8% | 174.05 | 54.60 |
| 2019 | 70.70 | +4.4% | 87.30 | 62.05 |
| 2018 | 67.75 | −30.6% | 99.10 | 42.65 |
| 2017 | 97.60 | −11.2% | 141.90 | 96.80 |
| 2016BSE close | 109.90 | – | 182.50 | 107.65 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 208.30 | 208.50 | 197.10 | 204.18 | 201.77 | 44,68,183 | 50.3% |
| 22 Oct 2026 | 213.10 | 215.59 | 207.30 | 207.99 | 210.17 | 21,17,400 | 44.1% |
| 21 Oct 2026 | 222.39 | 222.88 | 204.15 | 213.58 | 213.26 | 35,13,386 | 45.3% |
| 19 Oct 2026 | 229.19 | 229.19 | 218.41 | 221.11 | 220.95 | 30,33,303 | 51.8% |
| 16 Oct 2026 | 226.00 | 229.00 | 220.62 | 226.00 | 226.05 | 22,37,178 | 48.8% |
| 15 Oct 2026 | 233.28 | 233.61 | 224.25 | 225.93 | 228.61 | 12,04,938 | 50.7% |
| 14 Oct 2026 | 235.80 | 235.80 | 231.95 | 232.98 | 233.22 | 12,11,855 | 68.8% |
| 13 Oct 2026 | 236.60 | 237.20 | 232.20 | 235.02 | 234.24 | 10,38,986 | 43.3% |
| 12 Oct 2026 | 236.45 | 241.90 | 234.50 | 235.88 | 238.84 | 14,10,257 | 44.3% |
| 9 Oct 2026 | 236.01 | 239.76 | 232.29 | 234.06 | 234.76 | 16,38,950 | 44.1% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Open offer history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 25 Feb 2016 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
Company details
- Legal name
- Viyash Scientific Limited
- NSE symbol
- VIYASH
- BSE code
- 512529
- ISIN
- INE807F01027
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Sep 1990 on BSE, Mar 2016 on NSE
- Face value
- ₹2
- Former symbols
- SEQUENT
- CIN
- L99999TS1985PLC196357
- Corporate identity number, the registrar of companies' code for it